NKTR | Ticker Profile - Titan Protect

NKTR

Nektar Therapeutics

Healthcare · Biotechnology · NCM

$57.32

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.21

Based on estimated future earnings — lower means cheaper

Rev Growth

+3.8%

Year-over-year revenue change

Profit Margin

-284.2%

How much profit the company keeps from each dollar of revenue

ROE

-53.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$150.50

+163% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

https://www.nektar.com

Country: United States Employees: 63 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.896

Good returns relative to risk taken

Kelly Fraction

0.0621

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.163

Returns exceed worst-case losses — strong risk profile

Annual Return

77.8%

Historical annualised return based on price data

Max Drawdown

-66.9%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.25

Moves slightly more than the broader market

52W High

$109.00

47% below the year high

52W Low

$7.99

617% above the year low

Avg Volume

1,000,400

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-7.93

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

24.89

Heavy leverage — higher financial risk if revenues decline

Current Ratio

10.21

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

9.85

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-352.3%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$56M

Total revenue over the last 12 months

Net Income

$-158,098,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$192.00

Target Median

$150.50

Target Low

$80.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go